Right vein, first time, every time.

MAKING SIMPLE  PROCEDURES SIMPLE

We're on a mission to improve the cannulation experience on both sides of the needle. Cannulation is often the first key procedural step in a patient's clinical care journey, but it's frequently filled with fear as clinicians often fail to find the right vein the first time. This can lead to pain, anxiety, complications, and delayed treatments. We're currently in product development to bring this concept to life and solve this painful problem for patients and health care providers around the world.

INTRODUCING VEINTECH

After coming together though and winning the Perth Biodesign program in 2019, Nikhilesh Bappoo, Nicholas Buckley & Dr Katherine Arenson have been pushing forward with their award winning design concept. With their bench prototype completed and alpha prototype in development, VeinTech are positioned to solve a common pain-point in health care around the world: the high rate of first pass cannulation failure rates. With their ultra portable hand held vein imaging device, the VeinWave, they aim to help clinicians successfully target the right vein, first time, every time.

THE PROBLEM

Since the advent of intravenous cannulas in the 1950’s, clinicians have used subjective judgement through visual examination and manual palpation to estimate the location and quality of veins to target with a needle for cannulation. 70 years on, the average insertion failure rate is still 40%, and up to 70% in individuals with difficult intravenous access (DIVAs) such as children, chemotherapy and obese patients. These unnecessary  failures results in pain and stress for both patients and clinicians, increasing the risk of complications and delaying care.

OUR SOLUTION

VeinWave is a handheld ultraportable unit designed to assist with visualising veins to target for cannulation. It is designed to minimize training requirements and cost, therefore allowing for widespread adoption. 

​

VeinWave aims to significantly reduce the first-pass failure rate of 40%. By finding the right veins faster, we envision better patient satisfaction, lower risks of complications and improved clinical efficiency.

​

In Australia alone, 10 million cannulas fail on first insertion every year, resulting in an AU$700 million burden. With a global increasing trend of chronic disease and obesity, the failure rate continues to grow, representing a significant market opportunity for VeinTech and the VeinWave technology.

INVESTORS

We acknowledge the Whadjuk people of the Noongar nation as the traditional custodians of the land on which we live and their continuing connection to land, sea and community. We pay our respects to the people, the culture and the elders past, present and emerging.